SCHEMBL14199034

SCHEMBL14199034

CCCc1nc(CC)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)nn12

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 20/20 0.87
PDE1A P54750 5/20 0.84
PDE1B Q01064 5/20 0.84
PDE1C Q14123 5/20 0.84
PDE6A P16499 3/20 0.84
PDE4B Q07343 3/20 0.84
PDE3B Q13370 3/20 0.84
PDE3A Q14432 3/20 0.84
PDE2A O00408 2/20 0.84
PDE6D O43924 2/20 0.84
PDE9A O76083 2/20 0.84
PDE6G P18545 2/20 0.84
PDE4A P27815 2/20 0.84
ADORA1 P30542 2/20 0.84
ADRA1A P35348 2/20 0.84
PDE6B P35913 2/20 0.84
PDE6C P51160 2/20 0.84
PDE4C Q08493 2/20 0.84
PDE4D Q08499 2/20 0.84
KCNH2 Q12809 2/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5530 0.93 PDE5A (1.00) PDE5APDE1APDE1BPDE1CPDE6A
SCHEMBL973867 0.93 PDE5A (0.85) PDE5APDE1APDE1BPDE1CPDE6A
Hydrochloric Acid SCHEMBL974740 0.92 PDE5A (0.98) PDE5APDE1APDE1BPDE1CPDE6A
Vardenafil SCHEMBL29390262 0.91 PDE5A (1.00) PDE5APDE1APDE1BPDE1CPDE6A
Vardenafil SCHEMBL5772 0.91 PDE5A (1.00) PDE5APDE1APDE1BPDE1CPDE6A
SCHEMBL12823078 0.91 PDE5A (0.80) PDE5APDE1APDE1BPDE1CPDE6A
SCHEMBL12823625 0.91 PDE5A (0.84) PDE5APDE1APDE1BPDE1CPDE6A
Vardenafil SCHEMBL5685 0.91 PDE5A (1.00) PDE5APDE1APDE1BPDE1CPDE6A
Vardenafil SCHEMBL973820 0.91 PDE5A (1.00) PDE5APDE1APDE1BPDE1CPDE6A
SCHEMBL12922553 0.90 PDE5A (0.94) PDE5APDE1APDE1BPDE1CPDE6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130059844-A1 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2013-03-07 US disclosed
US-20080085897-A1 Use of 2-alkoxyphenyl-substituted imidazotriazinones BAYER HEALTHCARE AG (DE) 2008-04-10 US disclosed
US-20080085897-A1 Use of 2-alkoxyphenyl-substituted imidazotriazinones BAYER HEALTHCARE AG (DE) 2008-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059844-A1 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE2A PDE5A 4/4885PDE1A 25/4885PDE1B 14/4885
US-20080085897-A1 Use of 2-alkoxyphenyl-substituted imidazotriazinones PDE3B, PDE3A, PDE2A PDE5A 4/4885PDE1A 24/4885PDE1B 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.